Sep 23, 2022 8:50am EDT Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting
Sep 19, 2022 8:50am EDT Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, featuring Peter Houghton, Ph.D.
Sep 14, 2022 8:50am EDT Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer
Aug 30, 2022 9:00am EDT Lantern Pharma CEO & President, Panna Sharma, to Speak at H.C. Wainwright’s 24th Annual Global Investment Conference in September 2022
Aug 08, 2022 4:01pm EDT Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights
Aug 01, 2022 7:00am EDT Lantern Pharma to Report Second Quarter 2022 Operating & Financial Results on August 8th, 2022 at 4:30 p.m. ET
Jul 14, 2022 7:00am EDT Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer
May 12, 2022 7:00am EDT Lantern Pharma to Host Virtual KOL Event on Glioblastoma Multiforme (GBM) with Collaborators from Johns Hopkins during Brain Tumor Awareness Month
May 05, 2022 7:00am EDT Lantern Pharma Management to Speak at Multiple Investor and Scientific Conferences in May 2022
May 03, 2022 4:01pm EDT Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights
